Healthcare Pharma launches Eli Lilly's new diabetes drug in Bangladesh
Dhaka, Nov. 12 -- Healthcare Pharmaceuticals Ltd, one of the largest pharmaceutical companies in Bangladesh, has launched Eli Lilly & Company's Humalog(R) 200 for diabetes treatment in Bangladesh.
Humalog(R) 200 (Insulin Lispro 200 Units/ml) KwikPen(R)) is the concentrated, rapid acting analogue insulin designed to improve blood sugar control in adults with both Type 1 and Type 2 diabetic.
Humalog(R) 200 is US-Food and drug Administration approved medicine and manufactured by Eli Lilly & Company, said the company in a statement on Saturday.
Over time, some diabetic patients may require dosage increase of their insulin for improved glycaemic control.
Patients, who are obese, have high insulin resistance and require large daily dose of ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.